This inventor holds 1 USPTO granted patent. Top assignee: Janssen Pharmaceutica Nv. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Kenneth R LaMontagne, Jr: Innovator in Pyrimidine Kinase Inhibitors
Introduction
Kenneth R LaMontagne, Jr. is a notable inventor based in Morristown, NJ (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of kinase inhibitors. His work focuses on addressing chronic and acute diseases through innovative compounds.
Latest Patents
Kenneth holds a patent for "Substituted pyrimidine kinase inhibitors." This invention is directed to substituted pyrimidine compounds of formula (I) and their forms, which are synthesized for use in treating protein kinase-mediated diseases, disorders, or conditions. He has 1 patent to his name, showcasing his expertise in this specialized area.
Career Highlights
Kenneth is currently employed at Janssen Pharmaceutica NV, a leading pharmaceutical company known for its commitment to innovation in healthcare. His role involves research and development of new therapeutic agents that can significantly impact patient care.
Collaborations
Throughout his career, Kenneth has collaborated with esteemed colleagues, including Jeannene Butler and Peter J Connolly. These partnerships have enhanced the research and development process, leading to advancements in the field.
Conclusion
Kenneth R LaMontagne, Jr. exemplifies the spirit of innovation in the pharmaceutical industry. His work on pyrimidine kinase inhibitors represents a crucial step forward in treating various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile